The Effects of Soluble Corn Fiber on Gastrointestinal Tolerance and Fecal Microbiome in Healthy Children

January 27, 2022 updated by: Tate & Lyle

A Randomized, Controlled, Crossover Study to Assess the Effects of Soluble Corn Fiber on Gastrointestinal Tolerance and Fecal Microbiome in Healthy Children

The purpose of this study is to compare the effects of PROMITOR® Soluble Corn Fiber versus inulin on GI symptoms (tolerance), stool consistency (laxation) and fecal microbiome at levels that could contribute to closing the fiber gap. The dose response effects of PROMITOR® Soluble Corn Fiber in healthy children will also be compared.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

After initial site visits and randomization children were given a packet of powdered fiber to be mixed into a beverage daily. There were four test arms, described elsewhere. Each study arm lasted 10 days with an 18 day washout in between study periods.

Study Type

Interventional

Enrollment (Actual)

44

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Illinois
      • Addison, Illinois, United States, 60101
        • Biofortis Innovation Services

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

3 years to 9 years (CHILD)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Male or female, 3-9 years of age, inclusive at Visit 1 (Day -7)
  2. Potty trained
  3. Bowel movement at least every other day.
  4. Regularly consumes breakfast (at least 5 times/week) and agrees to consume breakfast every day during each test period.
  5. Willing to maintain physical activity and exercise patterns, body weight, and habitual diet throughout the trial.
  6. Willing to refrain from exclusionary medications, supplements, and products throughout the study.
  7. No health conditions that would prevent him/her from fulfilling the study requirements as judged by the Clinical Investigator on the basis of medical history.
  8. Caregiver understands the study procedures and signs forms providing informed consent to participate in the study and authorizes the release of relevant protected health information to the Clinical Investigator and subject provides informed assent.

Exclusion criteria

  1. Regular (>2/week) moderate to severe GI symptoms (as reported by subject and/or caregiver at Visit 1, Day -7). Mild and infrequent (≤ 2/week) GI symptoms are allowed.
  2. Subject will be away from caregiver for more than 1 day during the 3-day baseline period (Days -3, -2, and -1) and >48 consecutive hours during the 10 days of study product consumption during each test period. Goal is to recruit subjects who will be with their caregiver all or most of the time to minimize missing data.
  3. Clinically important GI conditions that would potentially interfere with the evaluation of the study product [e.g., inflammatory bowel disease, irritable bowel syndrome, gastric reflux, indigestion, dyspepsia, Crohn's disease, celiac disease, gastroparesis, and clinically significant lactose and gluten intolerance or other food or ingredient allergies which includes allergies to milk, eggs, peanuts, tree nuts, wheat and soy (Appendix 9)].
  4. Recent (within 2 weeks of Visit 1; Day -7) history of an episode of acute GI illness such as nausea/vomiting or diarrhea (defined as ≥ 3 loose or liquid stools/day).
  5. Caregiver-reported history (within 4 weeks of Visit 1; Day -7) of any constipation (<3 bowel movement/week) and diarrhea (≥3 of more loose stools/day) at the discretion of the Clinical Investigator.
  6. Uncontrolled and/or clinically important pulmonary (including uncontrolled asthma), cardiac (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke), hepatic, renal, endocrine (including Type 1 and Type 2 diabetes mellitus), hematologic, immunologic, neurologic, neurological (e.g., depression and/or anxiety disorders) or biliary disorders. Conditions which are well-controlled or resolved will be assessed by the Clinical Investigator on a case-by-case basis.

  7. Uncontrolled hypertension determined by the blood pressure measured at Visit 1 (Day -7) and defined as (https://www.emedicinehealth.com/pediatric_vital_signs/article_em.htm):

    • Children 3-5 years old: Systolic blood pressure >107 mm Hg and diastolic blood pressure >71 mm Hg
    • Children 6-9 years old: Systolic blood pressure >110 mm Hg and diastolic blood pressure >73 mm Hg One re-test will be allowed on a separate day prior to Visit 2 (Day 0), for subjects whose blood pressure exceeds either of these cut points at Visit 1 (Day -7), in the judgment of the Clinical Investigator.
  8. Extreme dietary habits as determined using the Diet Questionnaire (Appendix 2) and at the discretion of the Clinical Investigator.
  9. History or presence of cancer in the prior 2 years, except for non-melanoma skin cancer.
  10. Major trauma or any other surgical event within 3 months of Visit 1 (Day -7).
  11. Signs or symptoms of an active infection of clinical relevance within 5 days of Visit 1 (Day -7). The visit may be rescheduled such that all signs and symptoms have resolved (at the discretion of the Clinical Investigator) at least 5 days prior to Visit 1 (Day -7).*
  12. Weight loss or gain >4.5 kg in the 3 months prior to Visit 1 (Day -7).
  13. Currently or planning to be on a weight loss regimen during the study.
  14. Antibiotic use within 3 months of Visit 1 (Day -7).
  15. Use of steroids within 1 month of Visit 1 (Day -7).
  16. Chronic use (i.e., daily on a regular basis) of anti-inflammatory medications (e.g., NSAIDs) within 1 month of Visit 1 (Day -7).
  17. Use of medications (over-the-counter or prescription) and/or dietary supplements, known to influence GI function, including but not limited to prebiotics or probiotics, laxatives, enemas, fiber supplements and/or suppositories, antacids, anti-diarrheal agents, and/or anti-spasmodic within 2 weeks of Visit 1 (Day -7). Standard multivitamin and mineral supplements are allowed. Clinic staff will check ingredient lists of supplements for presence of prebiotics or probiotics.
  18. Use of allergy medications (prescription or over the counter) for >2 times/week within 2 weeks of Visit 1 (Day -7).
  19. Exposure to any non-registered drug product within 4 weeks prior to Visit 1 (Day -7).

  20. Has a condition the Clinical Investigator believes would interfere with his/her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results, or put the subject at undue risk.

    • If an infection occurs during the study period, test visits will be rescheduled until signs and symptoms have resolved (at the discretion of the Clinical Investigator) at least 5 days prior to study visits.

5.4.3 Excluded Products

  • Antibiotics within 3 months of Visit 1 (Day -7) and throughout the study period.
  • Steroids within 1 month of Visit 1 (Day -7) and throughout the study period.
  • Chronic use (i.e., daily on a regular basis) of anti-inflammatory medications (e.g., NSAIDs) within 1 month of Visit 1 (Day -7) and throughout the study period.
  • Medications (over-the-counter or prescription) and/or dietary supplements known to influence GI function, including but not limited to prebiotics or probiotics, laxatives, enemas, fiber supplements and/or suppositories, antacids, anti-diarrheal agents, and/or anti-spasmodic excluded within 2 weeks of Visit 1 (Day -7) and throughout the study period. Standard multivitamin and mineral supplements are allowed.
  • Allergy medications of >2 times/week within 2 weeks of Visit 1 (Day -7). Consumption of any of these excluded products during the study period should be documented and subjects may be excluded from the Per Protocol population following a review of protocol deviations at the end of the intervention. Should a subject require any of these excluded products, the study staff should consult with the Clinical Investigator and/or designee to determine future action (e.g., early termination, extension of washout period, etc.)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: OTHER
  • Allocation: RANDOMIZED
  • Interventional Model: CROSSOVER
  • Masking: TRIPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: Low-dose inulin
3-5 years old: 3g of fiber/day from inulin mixed in a beverage 6-9 years old: 5g of fiber/day from inulin mixed in a beverage
Other: Inulin
Inulin, a dietary fiber, will be given in a beverage daily in doses 3g, 5g, 6g, or 8g dependent on arm and age of participants.
EXPERIMENTAL: Low-dose soluble corn fiber
3-5 years old: 3g of fiber/day from soluble corn fiber mixed in a beverage 6-9 years old: 5g of fiber/day from soluble corn fiber mixed in a beverage
Other: soluble corn fiber
soluble corn fiber, a dietary fiber, will be given in a beverage daily in doses 3g, 5g, 6g, or 8g dependent on arm and age of participants.
ACTIVE_COMPARATOR: High-dose inulin
3-5 years old: 6g of fiber/day from inulin mixed in a beverage 6-9 years old: 8g of fiber/day from inulin mixed in a beverage
Other: Inulin
Inulin, a dietary fiber, will be given in a beverage daily in doses 3g, 5g, 6g, or 8g dependent on arm and age of participants.
EXPERIMENTAL: High-dose soluble corn fiber
3-5 years old: 6g of fiber/day from soluble corn fiber mixed in a beverage 6-9 years old: 8g of fiber/day from soluble corn fiber mixed in a beverage
Other: soluble corn fiber
soluble corn fiber, a dietary fiber, will be given in a beverage daily in doses 3g, 5g, 6g, or 8g dependent on arm and age of participants.
NO_INTERVENTION: Baseline
3-9 years old: pre-intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
GI Tolerance Composite Score
Time Frame: 10 day study period
The electronic Bedtime GITQ contains a series of questions regarding the presence and severity of GI symptoms occurring from start of study product consumption in the morning until bedtime. The electronic Morning GITQ contains a series of questions regarding the presence and severity of GI symptoms occurring from bedtime until immediately prior to the consumption of study product the next morning. Individual GI symptoms include: gas/flatulence, abdominal cramping, abdominal distention/bloating, borborygmus/stomach rumbling, burping, and nausea and their severity is ranked on a 4-point scale ranging from none to severe.
10 day study period

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Effects of consuming soluble corn fiber on individual GI symptoms
Time Frame: Baseline, Days 1,2, 3,5,7 and 10 of each study product period.
The electronic Bedtime GITQ contains a series of questions regarding the presence and severity of GI symptoms occurring from start of study product consumption in the morning until bedtime. The electronic Morning GITQ contains a series of questions regarding the presence and severity of GI symptoms occurring from bedtime until immediately prior to the consumption of study product the next morning. Individual GI symptoms include: gas/flatulence, abdominal cramping, abdominal distention/bloating, borborygmus/stomach rumbling, burping, and nausea and their severity is ranked on a 4-point scale ranging from none to severe.
Baseline, Days 1,2, 3,5,7 and 10 of each study product period.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dose response effects of soluble corn fiber on GI tolerance, stool consistency and bowel habits and fecal microbiome
Time Frame: up to 10 days

Caregivers will be asked to help subjects complete an electronic BHD-BSS during the 3 days immediately prior to Visit 2 (Day 0) for collection of baseline information. Caregivers will also be asked to help subjects complete the BHD-BSS every day during the 10 days of study product consumption during each test period. If bowel movement occurs while the subject is not in close proximity to the caregiver (e.g., when subject is at school), the caregivers will be instructed to record the time of the bowel movement as best as possible, but not complete any other details (e.g., straining, consistency, etc) about that particular bowel movement. The diary will provide information on stool frequency and consistency, straining and discomfort during bowel movement, and any sensation of incomplete evacuation. Caregivers will be provided instructions on how to access the electronic BHD-BSS at Visit 1 (Day -7).

Fecal samples will be collected using Omnigene®-GUT DNA Genotek per manufacturer's
up to 10 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Tate & Lyle

Collaborators

Biofortis Innovation Services

Investigators

  • Principal Investigator: Kathleen Kelley, Biofortis Innovation Services

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

May 20, 2021

Primary Completion (ACTUAL)

October 28, 2021

Study Completion (ACTUAL)

October 28, 2021

Study Registration Dates

First Submitted

December 30, 2021

First Submitted That Met QC Criteria

January 27, 2022

First Posted (ACTUAL)

January 28, 2022

Study Record Updates

Last Update Posted (ACTUAL)

January 28, 2022

Last Update Submitted That Met QC Criteria

January 27, 2022

Last Verified

January 1, 2022

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • BIO-2108

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gastrointestinal Tolerance

Clinical Trials on Inulin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe